Tobacco consumption is a reversible risk factor associated with reduced successful treatment outcomes of anti-tuberculosis therapy

International Journal of Infectious Diseases

Volumn 16, Issue 2, 2012, Pages

  Chiang, Yi Chun ^a,b   Lin, You Meei ^a,c   Lee, Jen Ai ^a   Lee, Chun Nin ^c   Chen, Hsiang Yin ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Drug therapy; Risk factors; Smoking; Treatment outcome; Tuberculosis

Indexed keywords

CREATININE; ETHAMBUTOL; ISONIAZID; NITROGEN; PYRAZINAMIDE; RIFAMPICIN; UREA;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS; HUMAN; HYPERTENSION; HYPERURICEMIA; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; SMOKING; TREATMENT OUTCOME; TUBERCULOSIS; UREA NITROGEN BLOOD LEVEL; VISUAL DISORDER;

AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84856008496     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.10.007     Document Type: Article

References (43)

1. UN Department of Economic and Social Affairs. The Millennium Development Goals Report 2010. New York, USA: UN Department of Economic and Social Affairs; 2010.
2. Stop TB Partnership, World Health Organization. Global plan to stop TB 2006-2015. WHO/HTM/TB/2006.35. Geneva, Switzerland: World Health Organization; 2006.
3. Stop TB Partnership, World Health Organization. The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millennium Development Goals. WHO/HTM/TB/2006.368. Geneva, Switzerland: World Health Organization; 2006.
4. Wang P.D. Epidemiology and control of tuberculosis in Taipei. J Infect 2002, 45:82-87.
5. Wobeser W., Yuan L., Naus M. Outcome of pulmonary tuberculosis treatment in the tertiary care setting-Toronto 1992/93. CMAJ 1999, 160:789-794.
6. Bustamante-Montes L.P., Escobar-Mesa A., Borja-Aburto V.H., Gómez-Muñoz A., Becerra-Posada F. Predictors of death from pulmonary tuberculosis: the case of Veracruz, Mexico. Int J Tuberc Lung Dis 2000, 4:208-215.
7. Connolly C., Davies G.R., Wilkinson D. Who fails to complete tuberculosis treatment? Temporal trends and risk factors for treatment interruption in a community-based directly observed therapy programme in a rural district of South Africa. Int J Tuberc Lung Dis 1999, 3:1081-1087.
8. Santha T., Garg R., Frieden T.R., Chandrasekaran V., Subramani R., Gopi P.G., et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis 2002, 6:780-788.
9. Chan-Yeung M., Noertjojo K., Leung C.C., Chan S.L., Tam C.M. Prevalence and predictors of default from tuberculosis treatment in Hong Kong. Hong Kong Med J 2003, 9:263-268.
10. Samman Y., Krayem A., Haidar M., Mimesh S., Osoba A., Al-Mowaallad A., et al. Treatment outcome of tuberculosis among Saudi nationals: role of drug resistance and compliance. Clin Microbiol Infect 2003, 9:289-294.
11. Mangura B., Napolitano E., Passannante M., Sarrel M., McDonald R., Galanowsky K., et al. Directly observed therapy (DOT) is not the entire answer: an operational cohort analysis. Int J Tuberc Lung Dis 2002, 6:654-661.
12. Pablos-Méndez A., Knirsch C.A., Barr R.G., Lerner B.H., Frieden T.R. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997, 102:164-170.
13. Slama K., Chiang C.Y., Enarson D.A., Hassmiller K., Fanning A., Gupta P., et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis 2007, 11:1049-1061.
14. Bates M.N., Khalakdina A., Pai M., Chang L., Lessa F., Smith K.R. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med 2007, 167:335-342.
15. Lin H.H., Ezzati M., Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med 2007, 4:e20.
16. Leung C.C., Lam T.H., Ho K.S., Yew W.W., Tam C.M., Chan W.M., et al. Passive smoking and tuberculosis. Arch Intern Med 2010, 170:287-292.
17. Altet-Gômez M.N., Alcaide J., Godoy P., Romero M.A., Hernández del Rey I. Clinical and epidemiological aspects of smoking and tuberculosis: a study of 13,038 cases. Int J Tuberc Lung Dis 2005, 9:430-436.
18. Gullón Blanco J.A., Suárez Toste I., Lecuona Fernández M., Galindo Morales R., Fernández Alvarez R., Rubinos Cuadrado G., et al. Tobacco smoking and sputum smear conversion in pulmonary tuberculosis. Med Clin (Barc) 2007, 128:565-568.
19. Horsburgh C.R., Feldman S., Ridzon R. Infectious Diseases Society of America. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 2000, 31:633-639.
20. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. WHO/CDS/TB/2003.313. Geneva, Switzerland: World Health Organization; 2003.
21. Blumberg H.M., Burman W.J., Chaisson R.E., Daley C.L., Etkind S.C., Friedman L.N., et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603-662.
22. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
23. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
24. Danan G., Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993, 46:1323-1330.
25. Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 46:1331-1336.
26. Dooley K.E., Tang T., Golub J.E., Dorman S.E., Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009, 80:634-639.
27. Wang C.S., Yang C.J., Chen H.C., Chuang S.H., Chong I.W., Hwang J.J., et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009, 137:203-210.
28. Zevin S., Benowitz N.L. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999, 36:425-438.
29. Guthikonda S., Sinkey C., Barenz T., Haynes W.G. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003, 107:416-421.
30. Benowitz N.L., Peng M., Jacob P. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther 2003, 74:468-474.
31. Dube MF, Green CR. Recent advances in tobacco science. Volume 8: methods of collection of smoke for analytical purposes. Symposium on the Formation, Analysis and Composition of Tobacco Smoke. The 36th Tobacco Chemists Research Conference, Raleigh, NC, October 24-27, 1982; p. 42-102. Available at: (accessed July 4, 2011). http://tobaccodocuments.org/lor/88248331-8517A.html.
32. Jenkins R.A., Guerin M.R., Tomkins B.A. The chemistry of environmental tobacco smoke: composition and measurement. 2nd ed 2000, CRC Press, Boca Raton, FL.
33. Vilchèze C., Weinrick B., Wong K.W., Chen B., Jacobs W.R. NAD+ auxotrophy is bacteriocidal for the tubercle bacilli. Mol Microbiol 2010, 76:365-377.
34. Greenstein R.J., Su L., Brown S.T. Growth of M. avium subspecies paratuberculosis in culture is enhanced by nicotinic acid, nicotinamide, and α and β nicotinamide adenine dinucleotide. Dig Dis Sci 2011, 56:368-375.
35. Siddiqi K., Lee A.C. An integrated approach to treat tobacco addiction in countries with high tuberculosis incidence. Trop Med Int Health 2009, 14:420-428.
36. Saukkonen J.J., Cohn D.L., Jasmer R.M., Schenker S., Jereb J.A., Nolan C.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952.
37. Chang K.C., Leung C.C., Tam C.M. Risk factors for defaulting from anti-tuberculosis treatment under directly observed treatment in Hong Kong. Int J Tuberc Lung Dis 2004, 8:1492-1498.
38. Twu S.J., Huang Y.F., Lai A.C., Ming N., Su I.J. Update and projection on HIV/AIDS in Taiwan. AIDS Educ Prev 2004, 16(3 Suppl A):53-63.
39. Yang C.H., Yang S.Y., Shen M.H., Kuo H.S. The changing epidemiology of prevalent diagnosed HIV infections in Taiwan, 1984-2005. Int J Drug Policy 2008, 19:317-323.
40. Burman W.J., Cohn D.L., Rietmeijer C.A., Judson F.N., Sbarbaro J.A., Reves R.R. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest 1997, 111:1168-1173.
41. Salles C.L., Conde M.B., Hofer C., Cunha A.J., Calçada A.L., Menezes D.F., et al. Defaulting from anti-tuberculosis treatment in a teaching hospital in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2004, 8:318-322.
42. Operating manual of payment for medical costs of tuberculosis using public budget [in traditional Chinese]. Taipei, Taiwan: Centers for Disease Control; March 1, 2010. Available at: (accessed July 27, 2010). http://www.cdc.gov.tw/public/Attachment/02414463671.doc.
43. Hsueh P.R., Liu Y.C., So J., Liu C.Y., Yang P.C., Luh K.T. Mycobacterium tuberculosis in Taiwan. J Infect 2006, 52:77-85.